

Simona Colla

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/757879/publications.pdf>

Version: 2024-02-01

18
papers

4,066
citations

687335

13
h-index

794568

19
g-index

20
all docs

20
docs citations

20
times ranked

7017
citing authors

#	ARTICLE	IF	CITATIONS
1	Telomere dysfunction induces metabolic and mitochondrial compromise. <i>Nature</i> , 2011, 470, 359-365.	27.8	1,093
2	The molecular classification of multiple myeloma. <i>Blood</i> , 2006, 108, 2020-2028.	1.4	997
3	A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. <i>Blood</i> , 2007, 109, 2276-2284.	1.4	831
4	Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. <i>Lancet Oncology</i> , 2017, 18, 100-111.	10.7	296
5	Passenger deletions generate therapeutic vulnerabilities in cancer. <i>Nature</i> , 2012, 488, 337-342.	27.8	294
6	CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. <i>Blood</i> , 2007, 109, 4995-5001.	1.4	139
7	ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma. <i>Cancer Cell</i> , 2017, 32, 88-100.e6.	16.8	114
8	Telomere Dysfunction Drives Aberrant Hematopoietic Differentiation and Myelodysplastic Syndrome. <i>Cancer Cell</i> , 2015, 27, 644-657.	16.8	85
9	NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. <i>Blood Advances</i> , 2019, 3, 922-933.	5.2	84
10	KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice. <i>Blood Advances</i> , 2018, 2, 2491-2504.	5.2	29
11	Telomere dysfunction instigates inflammation in inflammatory bowel disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	28
12	Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. <i>Nature Medicine</i> , 2022, 28, 557-567.	30.7	26
13	Dysfunctional telomeres and hematological disorders. <i>Differentiation</i> , 2018, 100, 1-11.	1.9	16
14	Hematopoiesis under telomere attrition at the single-cell resolution. <i>Nature Communications</i> , 2021, 12, 6850.	12.8	15
15	EZH2 Inhibitors: The Unpacking Revolution. <i>Cancer Research</i> , 2022, 82, 359-361.	0.9	9
16	Downregulation of <i>Protection of Telomeres 1</i> expression in myelodysplastic syndromes with 7q deletion. <i>British Journal of Haematology</i> , 2016, 173, 161-165.	2.5	4
17	RNA processing: a new player of genomic instability in multiple myeloma. <i>Oncoscience</i> , 2017, 4, 73-74.	2.2	3
18	Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia. <i>Leukemia</i> , 2022, 36, 2097-2107.	7.2	2